 "Dishman Pharma gains on USFDA inspection of Bavla facility")
Dishman Pharmaceuticals & Chemcials was trading higher by 6% to Rs 144 on the Bombay Stock Exchange after the company on Saturday announced inspection of its Bavla plant has been successfully completed by the United States Food and Drug Administration (USFDA).
“The renewal of US FDA inspection of Company’s Bavla facility has been successfully completed on July 08, 2016,” Dishman Pharmaceuticals and Chemicals said in a BSE filing.
The Bavla plant is mainly used for making pharmaceutical intermediate and active pharmaceutical ingredient (API's).
The stock hit a high of Rs 149 on the BSE in early morning trade. A combined 890,003 equity shares changed hands on the counter on the BSE and NSE till 09:44 AM.
“The renewal of US FDA inspection of Company’s Bavla facility has been successfully completed on July 08, 2016,” Dishman Pharmaceuticals and Chemicals said in a BSE filing.
The Bavla plant is mainly used for making pharmaceutical intermediate and active pharmaceutical ingredient (API's).
The stock hit a high of Rs 149 on the BSE in early morning trade. A combined 890,003 equity shares changed hands on the counter on the BSE and NSE till 09:44 AM.